The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex
NCT ID: NCT06686914
Last Updated: 2025-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
300 participants
INTERVENTIONAL
2025-06-30
2029-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Cannabidiol on the Driving Ability of Healthy Adults
NCT04590495
Cannabidiol Effects on Blood Alcohol Level and Intoxication
NCT06105138
Cannabidiol and Cannabis Concentrate Users
NCT06575751
Cannabidiol for Alcohol Use Disorder
NCT03904849
Effects of Cannabidiol (CBD) on the Brain
NCT04831294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cannabidiol (CBD) Oil 150mg
Cannabidiol (CBD) Oil, 150mg, 1 dose, 120 minutes prior to testing. After consumption of the respective treatment drug, the participant will be given a standardized meal and wait for 120 minutes to allow for drug absorption and for CBD to begin taking effect; this time frame was chosen based on the pharmacokinetics of CBD along with the consideration of participant burden (max absorption 2-5 hours; average half-life 17 hours).
Cannabidiol (CBD) Oil 150mg
Cannabidiol (CBD) Oil 150mg, 1 dose
Placebo Oil
Placebo Oil 1 dose 120 minutes prior to testing. After consumption of the respective treatment drug/placebo, the participant will be given a standardized meal and wait for 120 minutes to allow for drug absorption and for CBD to begin taking effect; this time frame was chosen based on the pharmacokinetics of CBD along with the consideration of participant burden (max absorption 2-5 hours; average half-life 17 hours).
Placebo Oil
Placebo Oil, 1 dose
Cannabidiol (CBD) Oil 300mg
Cannabidiol (CBD) Oil, 300mg, 1 dose, 120 minutes prior to testing. After consumption of the respective treatment drug, the participant will be given a standardized meal and wait for 120 minutes to allow for drug absorption and for CBD to begin taking effect; this time frame was chosen based on the pharmacokinetics of CBD along with the consideration of participant burden (max absorption 2-5 hours; average half-life 17 hours).
Cannabidiol (CBD) Oil 300mg
Cannabidiol (CBD) Oil 300mg, 1 dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cannabidiol (CBD) Oil 300mg
Cannabidiol (CBD) Oil 300mg, 1 dose
Cannabidiol (CBD) Oil 150mg
Cannabidiol (CBD) Oil 150mg, 1 dose
Placebo Oil
Placebo Oil, 1 dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Driven a motor vehicle at least once in the past 30 days
* Able to read English
* Test negative for all substances on a urine drug test and complete a test drive to ensure the absence of simulation sickness
* Not taking any daily prescription medications (excluding birth control)
* Not diagnosed with any serious chronic disease by a licensed healthcare provider (including but not limited to Alzheimer's and related dementias, Parkinson's disease or other neurodegenerative disorder, major depressive or anxiety disorder, schizophrenia or other serious mental illness, arrhythmias, cataracts, glaucoma, chronic obstructive pulmonary disease, diabetes, epilepsy, sleep apnea, and fibromyalgia)
* Have an individual willing to drive them home after testing or be taken home by study staff after testing
Exclusion Criteria
* Used illegal drugs in the past 30 days (e.g., cocaine/crack, heroin, methamphetamine, 3,4-methylenedioxy-methamphetamine, inhalants, phencyclidine, lysergic acid diethylamide, psilocybin mushrooms, or marijuana)
* Are pregnant or lactating at time of study
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
West Virginia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Toni Marie Rudisill
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toni M Rudisill, PhD
Role: PRINCIPAL_INVESTIGATOR
West Virginia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Virginia University
Morgantown, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2311874160
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.